News | August 16, 2022
QIAGEN launches syndromic test for QIAstat-Dx device to combat Monkeypox health emergency
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
The estimated capex is to the tune of Rs. 140 crore to be funded through debt and internal accrual
The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.
Meclizine Hydrochloride Tablets had estimated annual sales of USD 29 million in the U.S.
The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022, according to IQVIA.
Quetiapine Extended-Release Tablets are indicated for the treatment of Schizophrenia, Bipolar disorder and adjunctive treatment of Major Depressive Disorder (MDD)
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
Man lost 54 Kgs in 6 months with MGB procedure
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Subscribe To Our Newsletter & Stay Updated
